Astrazeneca Pharma India Ltd launched an antiplatelet drug Brilinta (Ticagrelor) on 18 October 2012 in India. Brilinta that is an oral antiplatelet treatment of adult patients is used for treating acute coronary syndromes.
The drug has a property of preventing formation of new clots in the blood and eases its flow within the body. This helps in reducing the risks of cardiovascular attack like cardiovascular death and heart attacks. The drug got its approval for marketing the tablets by the name of Brilinta (Ticagrelor) by the Drug Controller General of India following the recommendations made by New Drug Advisory Committee in May 2012.
Antiplatelet Drug Brilinta launched by Astrazeneca Pharma
By Jagranjosh
Oct 18, 2012, 16:03 IST
Corporate/Bussiness Current Affairs 2012. Astrazeneca Pharma India Ltd launched an antiplatelet drug Brilinta (Ticagrelor) on 18 October 2012 in India
.jpg){kind=logo}
Your career begins here! At Jagranjosh.com, our vision is to enable the youth to make informed life decisions, and our mission is to create credible and actionable content that answers questions or solves problems for India’s share of Next Billion Users. As India’s leading education and career guidance platform, we connect the dots for students, guiding them through every step of their journey—from excelling in school exams, board exams, and entrance tests to securing competitive jobs and building essential skills for their profession. With our deep expertise in exams and education, along with accurate information, expert insights, and interactive tools, we bridge the gap between education and opportunity, empowering students to confidently achieve their goals.
-1760907338778.png)
Comments
All Comments (0)
Join the conversation